Top Stories
Sanofi eyes investment of up to $1.6 billion in Germany, Handelsblatt says
Global Banking & Finance Review®
Company
FRANKFURT (Reuters) – French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported on Monday.
FRANKFURT (Reuters) – French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin brand Lantus, newspaper Handelsblatt reported on Monday.
The paper cited German government sources as saying Sanofi changed course after initial considerations to transfer Lantus production to France and the company is now close to committing to an upgrade of the German site in Frankfurt’s Hoechst district.
Sanofi did not immediately respond to a request for comment.
Among recent wins by Germany’s ruling coalition to attract healthcare investments, Daiichi Sankyo said in February it would spend about 1 billion euros to boost its work on precision cancer drugs near Munich.
U.S. drugmaker Eli Lilly in November last year pledged to invest 2.3 billion euros to make obesity and diabetes drugs in Germany.
($1 = 0.9299 euros)
(Reporting by Ludwig Burger; Editing by Kim Coghill)
Investment refers to the act of allocating resources, usually money, in order to generate income or profit. This can include purchasing stocks, bonds, real estate, or other assets.
Frankfurt is significant in the pharmaceutical industry as it hosts major production sites for companies like Sanofi, contributing to the development and manufacturing of essential medications.
Explore more articles in the Top Stories category
